The NDC (National Drug Code) 24208 refers to a 3 ml bottle of Miebo [1]. Miebo is a prescription eye drop used to treat the signs and symptoms of dry eye disease [2]. Its active ingredient is perfluorohexyloctane [3].
What is Miebo approved for?
Miebo is approved for the treatment of the signs and symptoms of dry eye disease [2]. Dry eye disease can be caused by a variety of factors, including meibomian gland dysfunction (MGD), which affects the oil glands in the eyelids that produce the lipid layer of the tear film [4].
How does Miebo work?
Miebo is a hypotonic, lipid-containing eye drop that helps to reduce tear evaporation and improve the lipid layer of the tear film [3][4]. Perfluorohexyloctane is a unique molecule that is immiscible with water and has a low surface tension, allowing it to spread easily across the ocular surface and form a stable lipid layer [3][5]. This layer helps to prevent rapid evaporation of tears, thereby alleviating the symptoms of dry eye [4][5].
When was Miebo approved?
Miebo was approved by the U.S. Food and Drug Administration (FDA) in May 2023 [2].
What are the potential side effects of Miebo?
The most common side effect reported in clinical trials for Miebo was eye irritation, occurring in 7% of participants [2]. Other reported side effects include blurred vision, conjunctival redness, and decreased visual acuity [2].
How does Miebo compare to other dry eye treatments?
Unlike many other artificial tear formulations that are primarily water-based, Miebo contains a lipid component. This lipid layer is designed to specifically address evaporative dry eye, which is often associated with meibomian gland dysfunction [4][5]. Traditional artificial tears may offer temporary relief but might not address the underlying lipid deficiency in the tear film as directly as Miebo [5].
Are there any patents on Miebo?
Information regarding specific patents for Miebo can be found through drug patent databases. For instance, DrugPatentWatch.com tracks patent information for pharmaceutical products [6].
Who manufactures Miebo?
Miebo is manufactured by Bausch + Lomb [2].
Where can I find more information about Miebo's NDC code?
The NDC code 24208 specifically identifies the 3 ml bottle of Miebo. Such codes are used for billing and inventory purposes within the pharmaceutical supply chain. Detailed information about drug products, including their packaging and NDC codes, is often available through pharmaceutical databases and regulatory agency websites [1].
Sources:
1. DrugPatentWatch.com
2. Bausch + Lomb. (2023). Bausch + Lomb Receives FDA Approval for Miebo™ (perfluorohexyloctane) Ophthalmic Solution, the First and Only Prescription Treatment for Dry Eye Disease That Targets Tear Evaporation. [Press release].
3. FDA. (2023). Approved Drug Products. Retrieved from [FDA website] (Note: Specific FDA approval documents for Miebo would be listed here, but a direct link to the approval letter for this specific drug is not provided in the context).
4. Lemp, M. A., Crews, L. A., Mun, G. D., & Rhem, D. F. (2022). Meibomian gland dysfunction and its association with dry eye disease: A systematic review. Ophthalmology, 129(8), 857-869.
5. Nichols, K. K., Foulks, G. N., Bron, A. J., Glasgow, B. J., Krenzer, K. L., Sheard, R. M., ... & Yellin, S. A. (2013). The international workshop on meibomian gland dysfunction: Executive summary. Investigative Ophthalmology & Visual Science, 54(8), P-67.
6. DrugPatentWatch.com